CompletedPhase 2NCT02104323

Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors

Studying Vestibular schwannoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Beijing Tiantan Hospital
Principal Investigator
Pinan Liu
Beijing Tiantan Hospital
Intervention
Endostatin(drug)
Enrollment
20 enrolled
Eligibility
16-30 years · All sexes
Timeline
2014 – 2016

Study locations (1)

Collaborators

Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02104323 on ClinicalTrials.gov

Other trials for Vestibular schwannoma

Additional recruiting or active studies for the same condition.

See all trials for Vestibular schwannoma →

← Back to all trials